NLRP3 and metabolic dysfunction-associated steatohepatitis: It is believed that through inhibition of NLRP3 inflammasome activation FTZ may work to interfere with the early lipid deposition process and the late induction of hepatic inflammation and fibrosis during the progression of NASH.